Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Depreciation (2016 - 2024)

Historic Accumulated Depreciation for Intellia Therapeutics (NTLA) over the last 10 years, with Q4 2024 value amounting to $49.7 million.

  • Intellia Therapeutics' Accumulated Depreciation rose 2466.07% to $49.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $49.7 million, marking a year-over-year increase of 2466.07%. This contributed to the annual value of $49.7 million for FY2024, which is 2466.07% up from last year.
  • Per Intellia Therapeutics' latest filing, its Accumulated Depreciation stood at $49.7 million for Q4 2024, which was up 2466.07% from $39.9 million recorded in Q4 2023.
  • Intellia Therapeutics' 5-year Accumulated Depreciation high stood at $49.7 million for Q4 2024, and its period low was $19.3 million during Q4 2020.
  • Its 5-year average for Accumulated Depreciation is $33.6 million, with a median of $33.2 million in 2022.
  • As far as peak fluctuations go, Intellia Therapeutics' Accumulated Depreciation surged by 3939.28% in 2020, and later skyrocketed by 2006.69% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Accumulated Depreciation stood at $19.3 million in 2020, then skyrocketed by 35.09% to $26.1 million in 2021, then rose by 27.13% to $33.2 million in 2022, then increased by 20.07% to $39.9 million in 2023, then increased by 24.66% to $49.7 million in 2024.
  • Its Accumulated Depreciation stands at $49.7 million for Q4 2024, versus $39.9 million for Q4 2023 and $33.2 million for Q4 2022.